Skip to main content
Lobe Sciences Ltd. logo

Lobe Sciences Ltd. — Investor Relations & Filings

Ticker · LOBE ISIN · CA53946V2066 CSE Manufacturing
Open in API
Filings indexed 419 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CA Canada
Listing CSE LOBE

About Lobe Sciences Ltd.

https://www.lobesciences.com/

Lobe Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for rare and underserved diseases with unmet medical needs. The company utilizes innovative technologies, including lipid technology, to advance its pipeline. Through its subsidiary, Cynaptec Pharmaceuticals, Lobe is developing L-130 (Conjugated Psilocin™), a patented formulation engineered to provide the therapeutic effects of psilocybin without the hallucinogenic properties. Its second subsidiary, Altemia, Inc., develops S-100, a novel medical food product intended for the dietary management and treatment of Sickle Cell Disease. The company's research targets conditions such as Chronic Cluster Headache and Sickle Cell Disease.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date (amended) - English.pdf
Regulatory Filings Classification · 82% confidence The document is a letter from the transfer agent to exchanges/commissions confirming that notice of record and meeting dates for the upcoming Annual General & Special Meeting has been sent. It does not include the actual proxy statement, meeting materials, or detailed financial data, nor is it reporting voting results. It simply serves as a general regulatory notification regarding meeting logistics. Therefore, it falls into the catch‐all Regulatory Filings category (RNS).
2026-05-22 English
Notice of the meeting and record date (amended) - English.pdf
Regulatory Filings Classification · 82% confidence The document is a notification letter from the company’s transfer agent confirming meeting and record dates for an Annual General & Special Meeting. It does not contain proxy materials themselves (so not PSI), nor is it an actual financial report, dividend notice, or voting results announcement. It is a routine compliance/filing notice sent to exchanges and regulators, which falls under the general Regulatory Filings category (RNS).
2026-05-22 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of the company's unaudited interim financial results for the second quarter of fiscal 2026, including financial highlights, operational updates, CEO comments, and subsequent financing events. It contains substantive financial data such as cash, working capital, R&D expenses, operating cash flow, and net loss for the quarter. The document also references the interim financial statements and management's discussion and analysis for Q2 2026, indicating it is a comprehensive interim report rather than a brief announcement or certification. The presence of detailed financial results and operational progress for a period shorter than a full fiscal year aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the appropriate classification is IR with high confidence. Q2 2026
2026-05-06 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2026-04-29 English
Interim MD&A - English.pdf
Regulatory Filings
2026-04-29 English
Interim financial statements/report – English.pdf
Regulatory Filings
2026-04-29 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.